Exudative Age-Related Macular Degeneration
Conditions
Keywords
Exudative age-related macular degeneration, anti-VEGF drug, Treat-and-extend, Conbercept
Brief summary
This is a prospective study. Data from patients diagnosed with nAMD who have never received related treatment were collected. Treatment was an intravitreal injection of 0.5 mg conbercept using modified T&E treatment plans. After three months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into two weeks and four weeks. Unlike the ALTAIR study, we cancel the maintenance criteria of classical T&E regimens. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), last injection interval, and the number of injections were recorded at 3, 6, 12, and 24 months to evaluate treatment efficacy.
Detailed description
This is a prospective study. Data from patients diagnosed with nAMD who have never received related treatment were collected. Treatment was an intravitreal injection of 0.5 mg conbercept using modified T&E treatment plans. After three months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into two weeks and four weeks. Unlike the ALTAIR study, we cancel the maintenance criteria of classical T&E regimens. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), last injection interval, and the number of injections were recorded at 3, 6, 12, and 24 months to evaluate treatment efficacy. Randomization and Interventions Conbercept (0.5 mg) was injected intravitreally once a month for 3 months, and then the patients were randomly divided into a 2-week group and a 4-week group. 2-week group: The injection interval was adjusted to 2 weeks. 4-week group: The injection interval was adjusted to 4 weeks. In the 2-week group, if the visual acuity decreased by less than 5 letters and the lesions showed no signs of exudative activity, such as rebleeding and increased oedema, the patients were followed up 6 weeks after the third injection and injected intravitreally once. If the condition remained stable, the follow-up was extended to 8 weeks , vitreous infusion was performed, and then the vitreous injection interval was gradually extended. If visual acuity decreased by more than 5 letters or the lesions showed rebleeding, increased oedema and other anatomical indicators worsened, a 4-week injection interval was maintained or reduced to 2 weeks based on the extended injection interval. In the 4-week group, the patients were followed up 8 weeks after the third injection and injected intravitreally once. If the condition remained stable, the follow-up was extended to 12 weeks, and vitreous injection was performed. Then, the vitreous injection interval was gradually extended.
Interventions
DRUGdifferent degrees of adjustment of the injection interval
Treatment was an intravitreal injection of 0.5 mg conbercept using modified T&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks.
Sponsors
First Affiliated Hospital of Chongqing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Peng Hui, chief physician of Ophthalmology Department of the First Affiliated Hospital of Chongqing Medical University, randomly divided the enrolled patients into two groups when they only knew the patient number and did not know the specific situation of the patient.
Eligibility
Sex/Gender
ALL
Age
55 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* age ≥50 years and meeting the diagnostic criteria for exudative AMD * OCTA suggesting the presence of subretinal neovascularization * no prior treatment (anti-VEGF, PDT, etc.) * best-corrected visual acuity (BCVA) between 5-75 letters in the study eye.
Exclusion criteria
* allergy to drugs needed in the diagnosis and treatment * a history of internal eye surgery (except surgery about cataract), trauma, or fundus laser photocoagulation * other ophthalmologic diseases besides nAMD or cataracts * renal insufficiency and severe cardiovascular and cerebrovascular diseases * surgery required due to vitreous hemorrhage during follow-up treatment * recent preparation for childbirth, pregnancy or lactation * poor compliance with diagnosis and treatment or difficulty conducting a regular outpatient review and cooperating with treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| mean change of the best-corrected visual acuity | baseline, every time before pre-intervention | change of the best-corrected visual acuity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mean change of central retinal thickness | baseline, every time before pre-intervention | change of central retinal thickness |
| mean time of last injection interval | up to 2 years | last injection interval |
| mean number of injections | up to 2 years | number of injections |
| the rate of complications or adverse reactions | up to 2 years | IOP, corneal epithelial defects, subconjunctival hemorrhage, secondary glaucoma, iatrogenic cataract, vitreous hemorrhage, endophthalmitis, systemic complications, |
Countries
China
Outcome results
None listed